{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:09:32Z","timestamp":1781629772901,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"DOI":"10.7759\/cureus.110970","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:33:21Z","timestamp":1781627601000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Abdominal Wall Angiosarcoma: A Case Report of Diagnostic Challenges, Local Recurrence, and Metastatic Progression"],"prefix":"10.7759","author":[{"given":"Jeevan","family":"Rivera-D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ocasio-Gar\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Matos-Llovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041152","article-title":"Trends in the incidence, survival, and prognostic nomogram of angiosarcoma in the United States","volume":"104","author":"Zeng D","year":"2025","unstructured":"Zeng D, Wang Z, Feng Y, McKay MJ, Masanam MK, Long H, Cao X. Trends in the incidence, survival, and prognostic nomogram of angiosarcoma in the United States. Medicine (Baltimore). 2025, 104:e41152. 10.1097\/MD.0000000000041152","journal-title":"Medicine (Baltimore)"},{"key":"ref2","article-title":"Angiosarcoma: a review of diagnosis and current treatment","volume":"9","author":"Cao J","year":"2019","unstructured":"Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019, 9:2303-13.","journal-title":"Am J Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6235","article-title":"Incidence and presenting characteristics of angiosarcoma in the US, 2001-2020","volume":"7","author":"Wagner MJ","year":"2024","unstructured":"Wagner MJ, Ravi V, Schaub SK, et al.. Incidence and presenting characteristics of angiosarcoma in the US, 2001-2020. JAMA Netw Open. 2024, 7:e246235. 10.1001\/jamanetworkopen.2024.6235","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1623327","article-title":"Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies","volume":"15","author":"Luong HT","year":"2025","unstructured":"Luong HT, Vercammen S, de Marco A, de Rooster H, Cosma A. Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies. Front Oncol. 2025, 15:1623327. 10.3389\/fonc.2025.1623327","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-021-01129-9","article-title":"Imaging features of primary sites and metastatic patterns of angiosarcoma","volume":"12","author":"Bhaludin BN","year":"2021","unstructured":"Bhaludin BN, Thway K, Adejolu M, et al.. Imaging features of primary sites and metastatic patterns of angiosarcoma. Insights Imaging. 2021, 12:189. 10.1186\/s13244-021-01129-9","journal-title":"Insights Imaging"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2022.107444","article-title":"Case report of an angiosarcoma of the abdominal wall during liraglutide injections: a coincidence?","volume":"97","author":"Bergeron E","year":"2022","unstructured":"Bergeron E, Dami M, Do XV, Vallee C, Noujaim J. Case report of an angiosarcoma of the abdominal wall during liraglutide injections: a coincidence?. Int J Surg Case Rep. 2022, 97:107444. 10.1016\/j.ijscr.2022.107444","journal-title":"Int J Surg Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15256","article-title":"Atypical presentation of cutaneous angiosarcoma: review of the literature","volume":"47","author":"Kostaki M","year":"2022","unstructured":"Kostaki M, Vourlakou C, Polydorou D, Stratigos AJ. Atypical presentation of cutaneous angiosarcoma: review of the literature. Clin Exp Dermatol. 2022, 47:1636-41. 10.1111\/ced.15256","journal-title":"Clin Exp Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204601","article-title":"Cutaneous angiosarcoma: a current update","volume":"70","author":"Shustef E","year":"2017","unstructured":"Shustef E, Kazlouskaya V, Prieto VG, Ivan D, Aung P. Cutaneous angiosarcoma: a current update. J Clin Pathol. 2017, 70:917-25. 10.1136\/jclinpath-2017-204601","journal-title":"J Clin Pathol"},{"key":"ref9","article-title":"","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. AJCC Cancer Staging Manual 8th Edition. Amin MB (ed): Springer, Chicago, IL; 2017."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-246","article-title":"Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis","volume":"36","author":"Machado I","year":"2021","unstructured":"Machado I, Giner F, Lavernia J, et al.. Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis. Histol Histopathol. 2021, 36:3-18. 10.14670\/HH-18-246","journal-title":"Histol Histopathol"},{"key":"ref11","unstructured":"Angiosarcoma. (2021). Accessed. March 23, 2026: https:\/\/www.pathologyoutlines.com\/topic\/softtissueangiosarcoma.html."},{"key":"ref12","article-title":"","author":"WHO Classification of Tumours Editorial Board","year":"2020","unstructured":"WHO Classification of Tumours Editorial Board. Soft Tissue and Bone\u00a0Tumours (5th ed., Vol 3). International Agency for Research on Cancer, Lyon (France); 2020. https:\/\/publications.iarc.fr\/588."},{"key":"ref13","unstructured":"CD34. (2023). Accessed. May 25, 2026: https:\/\/www.pathologyoutlines.com\/topic\/cdmarkerscd34.html."},{"key":"ref14","unstructured":"Factor VII related antigen. (2021). Accessed. May 25, 2026: https:\/\/www.pathologyoutlines.com\/topic\/stainsfactorviii.html."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01284-x","article-title":"FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis","volume":"24","author":"Cho U","year":"2024","unstructured":"Cho U, Cha HJ, Kim HJ, et al.. FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis. Clin Exp Med. 2024, 24:18. 10.1007\/s10238-023-01284-x","journal-title":"Clin Exp Med"},{"key":"ref16","unstructured":"Epithelial membrane antigen (EMA). (2021). Accessed. May 25, 2026: https:\/\/www.pathologyoutlines.com\/topic\/stainsema.html."},{"key":"ref17","article-title":"Atypical fibroxanthoma","author":"Kolb L","year":"2026","unstructured":"Kolb L, Villarreal LA, Schmieder GJ. Atypical fibroxanthoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.09.005","article-title":"Undifferentiated and dedifferentiated soft tissue neoplasms: immunohistochemical surrogates for differential diagnosis","volume":"38","author":"Thway K","year":"2021","unstructured":"Thway K, Fisher C. Undifferentiated and dedifferentiated soft tissue neoplasms: immunohistochemical surrogates for differential diagnosis. Semin Diagn Pathol. 2021, 38:170-86. 10.1053\/j.semdp.2021.09.005","journal-title":"Semin Diagn Pathol"},{"key":"ref19","unstructured":"Undifferentiated\/unclassified sarcoma. (2024). Accessed. May 25, 2026: https:\/\/www.pathologyoutlines.com\/topic\/softtissuemfhpleo.html."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001946","article-title":"Angiosarcoma-like Kaposi sarcoma: a distinctive histomorphologic variant representing an important diagnostic pitfall","volume":"46","author":"Plaza JA","year":"2022","unstructured":"Plaza JA, Sangueza OP, Giubellino A, Gru AA, Kaffenberger B, Wakely PE Jr, Sangueza MJ. Angiosarcoma-like Kaposi sarcoma: a distinctive histomorphologic variant representing an important diagnostic pitfall. Am J Surg Pathol. 2022, 46:1732-8. 10.1097\/PAS.0000000000001946","journal-title":"Am J Surg Pathol"},{"key":"ref21","unstructured":"Hemangioma & variants. (2022). Accessed. May 25, 2026: https:\/\/www.pathologyoutlines.com\/topic\/softtissuehemangioma.html."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0264-RS","article-title":"Anastomosing hemangioma: short review of a benign mimicker of angiosarcoma","volume":"144","author":"Lappa E","year":"2020","unstructured":"Lappa E, Drakos E. Anastomosing hemangioma: short review of a benign mimicker of angiosarcoma. Arch Pathol Lab Med. 2020, 144:240-4. 10.5858\/arpa.2018-0264-RS","journal-title":"Arch Pathol Lab Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13744","article-title":"Genomic landscape and preclinical models of angiosarcoma","volume":"19","author":"Benton A","year":"2025","unstructured":"Benton A, Liu B, Gartenhaus LE, Hanna JA. Genomic landscape and preclinical models of angiosarcoma. Mol Oncol. 2025, 19:965-83. 10.1002\/1878-0261.13744","journal-title":"Mol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo-Freire A","year":"2021","unstructured":"Espejo-Freire A, Elliott A, Rosenberg A, et al.. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers (Basel). 2021, 13:4816. 10.3390\/cancers13194816","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02651-4","article-title":"What is new in endothelial neoplasia?","volume":"476","author":"Papke DJ Jr","year":"2020","unstructured":"Papke DJ Jr, Hornick JL. What is new in endothelial neoplasia?. Virchows Arch. 2020, 476:17-28. 10.1007\/s00428-019-02651-4","journal-title":"Virchows Arch"},{"key":"ref26","article-title":"Stewart-Treves syndrome","author":"Murgia RD","year":"2023","unstructured":"Murgia RD, Gross GP. Stewart-Treves syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170039","article-title":"Angiosarcoma: clinical and imaging features from head to toe","volume":"90","author":"Gaballah AH","year":"2017","unstructured":"Gaballah AH, Jensen CT, Palmquist S, Pickhardt PJ, Duran A, Broering G, Elsayes KM. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol. 2017, 90:20170039. 10.1259\/bjr.20170039","journal-title":"Br J Radiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041176","article-title":"Lymphedema and obesity","volume":"12","author":"Sudduth CL","year":"2022","unstructured":"Sudduth CL, Greene AK. Lymphedema and obesity. Cold Spring Harb Perspect Med. 2022, 12:a041176. 10.1101\/cshperspect.a041176","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01544-0","article-title":"The impact of obesity on chronic oedema\/lymphoedema of the leg - an international multicenter cross-sectional study (LIMPRINT)","volume":"48","author":"Burian EA","year":"2024","unstructured":"Burian EA, Rungby J, Karlsmark T, N\u00f8rregaard S, Cestari M, Franks PJ, Moffatt CJ. The impact of obesity on chronic oedema\/lymphoedema of the leg - an international multicenter cross-sectional study (LIMPRINT). Int J Obes (Lond). 2024, 48:1238-47. 10.1038\/s41366-024-01544-0","journal-title":"Int J Obes (Lond)"},{"key":"ref30","article-title":"Survivorship (Version 2.2026). NCCN Clinical Practice Guidelines in Oncology. Available at: NCCN Survivorship Guidelines","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2026","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Survivorship (Version 2.2026). National Comprehensive Cancer Network, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1466."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/02683555211053532","article-title":"The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment","volume":"37","author":"Lurie F","year":"2022","unstructured":"Lurie F, Malgor RD, Carman T, et al.. The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment. Phlebology. 2022, 37:252-66. 10.1177\/02683555211053532","journal-title":"Phlebology"},{"key":"ref32","article-title":"Soft tissue sarcoma (Version","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2026","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma (Version 3.2026). National\u00a0Comprehensive Cancer Network, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1464."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001147","article-title":"Medical treatment of angiosarcomas","volume":"37","author":"Dufresne A","year":"2025","unstructured":"Dufresne A, Dupont M, Brahmi M. Medical treatment of angiosarcomas. Curr Opin Oncol. 2025, 37:372-6. 10.1097\/CCO.0000000000001147","journal-title":"Curr Opin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113321","article-title":"Optimal clinical management and the molecular biology of angiosarcomas","volume":"12","author":"Chen TW","year":"2020","unstructured":"Chen TW, Burns J, Jones RL, Huang PH. Optimal clinical management and the molecular biology of angiosarcomas. Cancers (Basel). 2020, 12:3321. 10.3390\/cancers12113321","journal-title":"Cancers (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano A","year":"2012","unstructured":"Italiano A, Cioffi A, Penel N, et al.. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012, 118:3330-6. 10.1002\/cncr.26599","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorc.2026.100376","article-title":"170p AI-assisted systematic review and pooled analysis of anthracycline- versus taxane-based chemotherapy in advanced or metastatic angiosarcoma","volume":"5","author":"Peddio A","year":"2026","unstructured":"Peddio A, D'Ambrosio S, Vitale F, et al.. 170p AI-assisted systematic review and pooled analysis of anthracycline- versus taxane-based chemotherapy in advanced or metastatic angiosarcoma. ESMO Rare Cancers. 2026, 5:100376.","journal-title":"ESMO Rare Cancers"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr138","article-title":"Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome","volume":"23","author":"Penel N","year":"2012","unstructured":"Penel N, Italiano A, Ray-Coquard I, et al.. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012, 23:517-23. 10.1093\/annonc\/mdr138","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0241","article-title":"Contemporary therapy for advanced soft-tissue sarcomas in adults: a review","volume":"2","author":"Pang A","year":"2016","unstructured":"Pang A, Carbini M, Maki RG. Contemporary therapy for advanced soft-tissue sarcomas in adults: a review. JAMA Oncol. 2016, 2:941-7. 10.1001\/jamaoncol.2016.0241","journal-title":"JAMA Oncol"},{"key":"ref39","unstructured":"U.S. Food and Drug Administration. doxorubicin hydrochloride injection. (2020). Accessed: May 25, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050467s078,050629s030lbl.pdf."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon B","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, et al.. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017, 18:1397-410. 10.1016\/S1470-2045(17)30622-8","journal-title":"Lancet Oncol"},{"key":"ref41","unstructured":"U.S. Food and Drug Administration. TAXOL\u00ae (Paclitaxel) injection. (2011). Accessed: May 25, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03819-9","article-title":"Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one center","volume":"20","author":"Fang C","year":"2025","unstructured":"Fang C, Zeng X, Ji Q, Zhu T, Fang M, Cao J. Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one center. Orphanet J Rare Dis. 2025, 20:298. 10.1186\/s13023-025-03819-9","journal-title":"Orphanet J Rare Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132101","article-title":"Visceral angiosarcoma: a nationwide population-based study from 2000-2017","volume":"17","author":"Rehn\u00e9 Jensen L","year":"2025","unstructured":"Rehn\u00e9 Jensen L, Holm CE, Tolstrup J, \u00d8rholt M, Petersen MM, Penninga L. Visceral angiosarcoma: a nationwide population-based study from 2000-2017. Cancers (Basel). 2025, 17:2101. 10.3390\/cancers17132101","journal-title":"Cancers (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14642-7","article-title":"Low overall survival after treatment for angiosarcoma: a single-centre retrospective observational cohort study of 64 patients","volume":"25","author":"Kjartansd\u00f3ttir S","year":"2025","unstructured":"Kjartansd\u00f3ttir S, Malchau E, Berger C, Styring E, Bergh P, Wennergren D. Low overall survival after treatment for angiosarcoma: a single-centre retrospective observational cohort study of 64 patients. BMC Cancer. 2025, 25:1378. 10.1186\/s12885-025-14642-7","journal-title":"BMC Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111780","article-title":"Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas","volume":"11","author":"Weidema ME","year":"2019","unstructured":"Weidema ME, Flucke UE, van der Graaf WT, et al.. Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers (Basel). 2019, 11:1780. 10.3390\/cancers11111780","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07300-7","article-title":"Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study","volume":"20","author":"Ren S","year":"2020","unstructured":"Ren S, Wang Y, Wang Z, Shao J, Ye Z. Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study. BMC Cancer. 2020, 20:778. 10.1186\/s12885-020-07300-7","journal-title":"BMC Cancer"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156139","article-title":"Clinicopathological features and prognostic insights of cutaneous versus non-cutaneous angiosarcoma: a retrospective single-center cohort study","volume":"273","author":"Voci D","year":"2025","unstructured":"Voci D, Grigorean A, Neuenschwander J, et al.. Clinicopathological features and prognostic insights of cutaneous versus non-cutaneous angiosarcoma: a retrospective single-center cohort study. Pathol Res Pract. 2025, 273:156139. 10.1016\/j.prp.2025.156139","journal-title":"Pathol Res Pract"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young RJ","year":"2014","unstructured":"Young RJ, Natukunda A, Liti\u00e8re S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014, 50:3178-86. 10.1016\/j.ejca.2014.10.004","journal-title":"Eur J Cancer"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6892","article-title":"Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute","volume":"14","author":"Wang L","year":"2017","unstructured":"Wang L, Lao IW, Yu L, Wang J. Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute. Oncol Lett. 2017, 14:5370-8. 10.3892\/ol.2017.6892","journal-title":"Oncol Lett"},{"key":"ref50","unstructured":"Protocol for the examination of resection specimens from patients with soft tissue tumors. (2024). Accessed. May 25, 2026: https:\/\/documents.cap.org\/protocols\/Soft.Tissue_4.2.0.0.REL_CAPCP.pdf."},{"key":"ref51","article-title":"Soft tissue masses: evaluation and treatment","volume":"105","author":"Achar SA","year":"2022","unstructured":"Achar SA, Yamanaka J, Oberstar J. Soft tissue masses: evaluation and treatment. Am Fam Physician. 2022, 105:602-12.","journal-title":"Am Fam Physician"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490721-primary-abdominal-wall-angiosarcoma-a-case-report-of-diagnostic-challenges-local-recurrence-and-metastatic-progression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:33:31Z","timestamp":1781627611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490721-primary-abdominal-wall-angiosarcoma-a-case-report-of-diagnostic-challenges-local-recurrence-and-metastatic-progression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.110970","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}